Skip to main content
Premium Trial:

Request an Annual Quote

Xantos to Use Atugen s RNAi Compounds for Cancer Target Validation

NEW YORK, April 15 (GenomeWeb News) - Xantos Biomedicine today announced an agreement to use Atugen's atuRNAi short interfering RNAi compounds to validate an angiogenic target in animal studies.

 

Atugen said that its atuRNAi gene-silencing approach has already been "successfully applied to validate and modulate disease targets in liver diseases and several animal models for cancer."

 

Financial details of the collaboration were not disclosed.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.